Abstract:Protein kinases play pivotal roles in various biological functions, influencing cell differentiation, promoting survival, and regulating the cell cycle. The disruption of protein kinase activity is intricately linked to pathways in tumor development. This manuscript explores the transformative impact of protein kinase inhibitors on cancer therapy, particularly their efficacy in cases driven by targeted mutations. Focusing on key tyrosine kinase inhibitors (TKIs) like Bcr-Abl, Epidermal Growth Factor Receptor (EGFR), and Vascular Endothelial Growth Factor Receptor (VEGFR), it targets critical kinase families in cancer progression. Clinical trial details of these TKIs offer insights into their therapeutic potentials. Learning from FDA-approved kinase inhibitors, the review dissects trends in kinase drug development since imatinib's paradigm-shifting approval in 2001. TKIs have evolved into pivotal drugs, extending beyond oncology. Ongoing clinical trials explore novel kinase targets, revealing the vast potential within the human kinome. The manuscript provides a detailed analysis of advancements until 2022, discussing the roles of specific oncogenic protein kinases in cancer development and carcinogenesis. Our exploration on PubMed for relevant and significant TKIs undergoing pre-FDA approval phase III clinical trials enriches the discussion with valuable findings. While kinase inhibitors exhibit lower toxicity than traditional chemotherapy in cancer treatment, challenges like resistance and side effects emphasize the necessity of understanding resistance mechanisms, prompting the development of novel inhibitors like osimertinib targeting specific mutant proteins. The review advocates thorough research on effective combination therapies, highlighting the future development of more selective RTKIs to optimize patient-specific cancer treatment and reduce adverse events.

Non-Receptor Tyrosine Kinases: Their Structure and Mechanistic Role in Tumor Progression and Resistance

Receptor Tyrosine Kinases: Biological Functions and Anticancer Targeted Therapy

Exploring receptor tyrosine kinases-inhibitors in Cancer treatments

Tumor Exome Sequencing and Copy Number Alterations Reveal Potential Predictors of Intrinsic Resistance to Multi-Targeted Tyrosine Kinase Inhibitors

Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective

From Tyrosine Kinases to Tyrosine Phosphatases: New Therapeutic Targets in Cancers and Beyond

Advances in studies of tyrosine kinase inhibitors and their acquired resistance

Pathogenesis Of Ron Receptor Tyrosine Kinase In Cancer Cells: Activation Mechanism, Functional Crosstalk, And Signaling Addiction

Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis—New insight and futuristic vision

Therapeutic advances of targeting receptor tyrosine kinases in cancer

Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy

Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors

Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges

Tyrosine kinases: multifaceted receptors at the intersection of several neurodegenerative disease-associated processes

Receptor tyrosine kinases in breast cancer treatment: unraveling the potential

Discovery of Tropomyosin Receptor Kinase Inhibitors as New Generation Anticancer Agents: A Review

Advances in Small-Molecule Inhibitors of Protein Tyrosine Kinases

Non-coding RNAs as potential therapeutic targets for receptor tyrosine kinase signaling in solid tumors: current status and future directions

Targeting PTPs with small molecule inhibitors in cancer treatment

Recent insights into the therapeutic strategies targeting the pseudokinase PTK7 in cancer